PMID- 21357792
OWN - NLM
STAT- MEDLINE
DCOM- 20110527
LR  - 20220321
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 29
IP  - 10
DP  - 2011 Apr 1
TI  - Prognostic significance and tumor biology of regional lymph node disease in 
      patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
PG  - 1304-11
LID - 10.1200/JCO.2010.29.4611 [doi]
AB  - PURPOSE: Regional lymph node disease (RLND) is a component of the risk-based 
      treatment stratification in rhabdomyosarcoma (RMS). The purpose of this study was 
      to determine the contribution of RLND to prognosis for patients with RMS. 
      PATIENTS AND METHODS: Patient characteristics and survival outcomes for patients 
      enrolled onto Intergroup Rhabdomyosarcoma Study IV (N = 898, 1991 to 1997) were 
      evaluated among the following three patient groups: nonmetastatic patients with 
      clinical or pathologic negative nodes (N0, 696 patients); patients with clinical 
      or pathologic positive nodes (N1, 125 patients); and patients with a single site 
      of metastatic disease (77 patients). RESULTS: Outcomes for patients with 
      nonmetastatic alveolar N0 RMS were significantly better than for patients with N1 
      RMS (5-year failure-free survival [FFS], 73% v 43%, respectively; 5-year overall 
      survival [OS], 80% v 46%, respectively; P < .001). Patients with a single site of 
      alveolar metastasis had even worse FFS and OS (23% FFS and OS, P = .01) when 
      compared with patients with N1 RMS; however, the differences was not as large as 
      the differences between patients with N0 RMS and N1 RMS. For embryonal RMS, there 
      was no statistically significant difference in FFS or OS (P = .41 and P = .77, 
      respectively) for patients with N1 versus N0 RMS. Gene array analysis of primary 
      tumor specimens identified that genes associated with the immune system and 
      antigen presentation were significantly increased in N1 versus N0 alveolar RMS. 
      CONCLUSION: RLND alters prognosis for alveolar but not embryonal RMS. For 
      patients with N1 disease and alveolar histology, outcomes were more similar to 
      distant metastatic disease rather than local disease. Current data suggest that 
      more aggressive therapy for patients with alveolar N1 RMS may be warranted.
FAU - Rodeberg, David A
AU  - Rodeberg DA
AD  - Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, USA. 
      rodebergd@ecu.edu
FAU - Garcia-Henriquez, Norbert
AU  - Garcia-Henriquez N
FAU - Lyden, Elizabeth R
AU  - Lyden ER
FAU - Davicioni, Elai
AU  - Davicioni E
FAU - Parham, David M
AU  - Parham DM
FAU - Skapek, Stephen X
AU  - Skapek SX
FAU - Hayes-Jordan, Andrea A
AU  - Hayes-Jordan AA
FAU - Donaldson, Sarah S
AU  - Donaldson SS
FAU - Brown, Kenneth L
AU  - Brown KL
FAU - Triche, Timothy J
AU  - Triche TJ
FAU - Meyer, William H
AU  - Meyer WH
FAU - Hawkins, Douglas S
AU  - Hawkins DS
LA  - eng
GR  - U10 CA24507/CA/NCI NIH HHS/United States
GR  - UL1 RR025014/RR/NCRR NIH HHS/United States
GR  - U10 CA098543/CA/NCI NIH HHS/United States
GR  - U10 CA024507/CA/NCI NIH HHS/United States
GR  - U10 CA98543/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
DEP - 20110228
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
SB  - IM
MH  - Canada
MH  - Chi-Square Distribution
MH  - Child
MH  - Child, Preschool
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - Infant
MH  - Kaplan-Meier Estimate
MH  - Lymph Nodes/*pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Neoplasm Staging
MH  - Proportional Hazards Models
MH  - Rhabdomyosarcoma, Alveolar/genetics/mortality/*secondary/therapy
MH  - Rhabdomyosarcoma, Embryonal/genetics/mortality/*secondary/therapy
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
MH  - United States
PMC - PMC3083998
COIS- Authors' disclosures of potential conflicts of interest and author contributions 
      are found at the end of this article.
EDAT- 2011/03/02 06:00
MHDA- 2011/05/28 06:00
PMCR- 2012/04/01
CRDT- 2011/03/02 06:00
PHST- 2011/03/02 06:00 [entrez]
PHST- 2011/03/02 06:00 [pubmed]
PHST- 2011/05/28 06:00 [medline]
PHST- 2012/04/01 00:00 [pmc-release]
AID - JCO.2010.29.4611 [pii]
AID - 94611 [pii]
AID - 10.1200/JCO.2010.29.4611 [doi]
PST - ppublish
SO  - J Clin Oncol. 2011 Apr 1;29(10):1304-11. doi: 10.1200/JCO.2010.29.4611. Epub 2011 
      Feb 28.